Clinical Trial Results:
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic
Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Summary
|
|
EudraCT number |
2011-000261-12 |
Trial protocol |
BE ES SE NL |
Global completion date |
13 Sep 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Aug 2016
|
First version publication date |
26 Aug 2016
|
Other versions |
|
Summary report(s) |
CNTO328MDS2001_2011-000261-12_CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.